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METHODS AND COMPOSITIONS FOR
TREATING NEUROLOGICAL DISORDERS

least one induction suppressor of inducible nitric oxide syn

thase, Wherein said induction suppressor is selected from the
group consisting of a kalirin polynucleotide or oligonucle
otide, a kalirin polypeptide, and/or an active fragment of a

STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH

kalirin polypeptide.
The invention provides a method of inhibiting nitric oxide

cytotoxicity comprising contacting a cell capable of produc

This invention Was supported in part by Grant Nos. RO1
HD18702 and R01 GM74101 and 5P50AG05144 awarded

ing nitric oxide With a biologically effective amount of an

by the National Institutes of Health. The government may
have certain rights in this invention.

tide, an active fragment of a kalirin polypeptide and/ or a

agent comprising a kalirin polynucleotide, a kalirin polypep

kalirin agonist that regulates inducible nitric oxide synthase
TECHNICAL FIELD

under conditions Wherein the agent reduces inducible nitric

oxide synthase activity.
This disclosure relates to methods and compositions useful
for the treatment of dementia. More particularly the disclo

5

The invention provides a composition comprising an active
fragment of kalirin in a pharmaceutically acceptable carrier.

sure relates to methods and compositions for the treatment of

The details of one or more embodiments of the invention

neurodegenerative diseases and disorders including senile
dementia and AlZheimer’s Disease (AD).
20

are set forth in the accompanying draWings and the descrip
tion beloW. Other features, objects, and advantages of the
invention Will be apparent from the description and draWings,
and from the claims.

BACKGROUND

Nitric oxide synthase (NOS) is an enZyme Which is found
in humans. Three isoforrns of NOS have been identi?ed. In

the body nNOS and eNOS are constitutively expressed in the
cells in Which they are found. However, iNOS is not consti
tutively expressed, but is knoWn to be induced by a number of

DESCRIPTION OF DRAWINGS

25

FIG. lA-C shoWs expression of kalirin. Hippocampal and
cerebellar specimens are numerically designated as AD 1-19

and control 1-15 throughout the ?gures and presented in the

cytokines, lipopolysaccarides (LPS), and other mediators of

same order. (A) GeneChip analysesithe mean values of

the in?ammatory response. Speci?cally, iNOS has been asso
ciated as indicating certain pathological disease states.
AlZheimer’s disease (AD) is the major cause of dementia
in the elderly. Although rare genetic forms of AD exist, most
patients are classi?ed as having sporadic AD, since no family

Kalirin, individual values of hippocampal specimens (HIP)
and cerebellar specimens (CER). Open bars for control, black

history is usually identi?ed. Pathologically, AD is character
iZed by neuronal and synaptic degeneration With an increased
number of senile plaques and neuro?brillary tangles com
pared to non-demented individuals of comparable age.
The senile plaques, characteristic of AlZheimer’s disease,

30

sample/control value, and the right side “Y” axis represents
the actual value. The means (bars) and standard deviations

(error bars) are presented. HIP:hippocampus and
CER:cerebellum. The marked samples shoW statistically sig
35

are composed of a central core of aggregated beta-amyloid, a

breakdown product of amyloid precursor protein (APP). The
neuro?brillary tangles are insoluble intracellular thread-like

40

structures made up of a hyperphosphorylated form of a pro

tein called tau, Which is associated With microtubles.
Early and accurate diagnosis of AlZheimer’s disease is
important since early intervention may delay or arrest the

reversible neuronal damage. Clinical diagnosis is not alWays

bars for AD. The left side “Y” axis represents the ratio of

45

accurate since the criteria are relatively subjective and the
disease needs to be differentiated from other dementing ill

ni?cant differences betWeen AD and control. The samples
With signi?cant differences are marked as (*) for p<0.0001
and (+) for 0.05<P>0.0001. Unmarked samples shoW no sig
ni?cant difference betWeen AD and control. These formats
are also used in all of FIGS. 1 and 2. (B) RT-PCR results
presented the same as in (A). The upper gel bands represent
Kalirin and the loWer bands GAPDH. (C) Real time PCR
results presented the same as in (A).
FIG. 2A-C shoWs immunoblots of Kalirin. An equal
amount of solubiliZed proteins from individual specimens
Was electrophoresed and blotted for Kalirin (upper blots) and

actin (loWer blots). (A) the mean values, (B) values of indi
vidual hippocampal specimens and (C) values of individual
cerebellar specimens as described in FIG. 1. The 209 kDa

nesses.

SUMMARY

50

The invention provides a method for diagnosing and moni
toring senile dementia or other neurodegenerative disease or

disorder in a subject comprising detecting a kalirin polypep
tide or polynucleotide in a sample derived from the subject,

(black bar) hippocampi (HIP) and cerebella (CER). The left
55

Wherein a reduction or mutation in kalirin is indicative of the
onset, progress or late stage of dementia.
The invention also provides a method for determine a sub

ject’s risk for senile dementia comprising: (a) obtaining a
sample derived from a subject; (b) detecting or identifying in
the sample a kalirin polypeptide or polynucleotide; and (c)

protein marker is indicated.
FIG. 3A-C shoWs activity and expression of iNOS. (A) The
average activities of iNOS for control (open bar) and AD
side Y axis represents the ratio of AD/control value, and the
right sideY axis represents the actual value. The means (bars)
and standard deviations (error bars) are presented. The

samples With statistically signi?cant differences betWeen AD
and control are marked as (*) for p<0.0001 and (+) for
0.05<P>0.0001. HIP:hippocampus and CER:cerebellum.
60

(HIP) The iNOS activity of individual control (open bar) and
AD (black bar) hippocampi. The samples Were sorted in the
order of increasing iNOS activity. (CER) The iNOS activity

comparing the detected amount With an amount detected for
a normal control, Wherein a reduction in kalirin is indicative

of individual cerebella as described above. (B) The average

or a risk of senile dementia.

cerebella. (HIP) Immunoblotted iNOS (upper blots) and actin
(loWer blots) concentrations of individual hippocampi.
(CER) Immunoblotted iNOS (upper blots) and actin (loWer

The invention further provides a method for suppressing
the induction of inducible nitric oxide synthase in a cell
comprising contacting said cell With an effective amount of at

concentration of immunoblotted iNOS of hippocampi and
65

blots) concentrations of individual cerebella. (C). The aver
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age amount of iNOS mRNA expression determined by

cloned into pcDNA 4. (E) AtT-20 cell line stably transfected

Affymetrix U133A chip. (HIP) iNOS mRNA concentration
of individual hippocampi. (CER) iNOS mRNA concentration

With iNOS Was transiently transfected With the pcDNA4 car

of individual cerebella.

and assayed for iNOS. The activities Were compared to the
activities of nontransfected cells (C), cells transfected With
the full length Kalirin-7 (F) and cells transfected With D2. In
addition, the cells Were solubiliZed, and 10% of the solubi

rying individual Kalirin section cDNAs With the Flag epitope

FIG. 4A-D shows activity and mRNA expression level of
eNOS and nNOS. (A) NOS activities, (B) gene chip data for
eNOS and (C) gene chip data for nNOS are presented as
described in FIG. 3C. (D) The average expression levels of
calmodulins, putative iNOS activators in the hippocampus in
the left panel and those in the cerebellum in the right panel.
FIG. 5A-C shoWs co-immunoprecipitation of Kalirin and
iNOS. (A) Left Panels: Ten percent of the pooled samples

liZed samples Were electrophoresed on polyacrylamide gel
(7.5% gel for C, F and D2, and 15% gel for sections 1-19) and

immunoblotted With anti-Flag (loWer panel). The blotted
bands of C, F and D2 Were aligned to those of sections 1-19 to
save space. The 5 kD maker is for the sections 1-19. (F)

AtT-20 cell line stably expressing iNOS Was transiently trans
fected With increasing amounts of the pcDNA4 carrying Kali

Were solubiliZed and immunoblotted With anti-Kalirin (upper

blot) or anti-iNOS (loWer blot). Right Panels: The pooled
samples Were immunoprecipitated With anti-iNOS beads or
anti-Kalirin beads and immunoblotted With anti-Kalirin or

rin section 8 cDNA and assayed for iNOS. The cells Were also

anti-iNOS, respectively (upper blots). In addition, the blot

fecting them With a constant amount of the pRL-TK vector

Was probed With rabbit anti-Flag or mouse anti-Flag, respec

encoding Renilla luciferase as described in (SA). The dotted
line represents the luciferase activity. The attempt to immu
noblot the cells With anti-Kalirin failed to recogniZe the Kali

tested for the toxic effect of the plasmid itself by co-trans

tively, as the negative immunoblot controls (loWer blots). (B)
Left Panel: The cells expressing Kalirin (K) and the cells
expressing iNOS (I) Were combined, solubiliZed, immuno
precipitated With anti-iNOS beads, and immunoblotted With
anti-Kalirin. In addition, 10% of the input and 10% of the
supernatant of the immunoprecipitation Were immunoblotted
With anti-Kalirin. When the cells co-expressing both Kalirin
and iNOS (KI) Were solubiliZed, immunoprecipitated With
anti-iNOS beads, and immunoblotted With anti-Kalirin, Kali

20

rin fragments.
FIG. 7A-C shoWs induction and attenuation of iNOS by

LPS (A-C), iNOS plasmid (A-C) andA [31-42 (C), and attenu
ation of iNOS by Kalirin (A-C) and inhibitors of NOS (B, C).
25

toma SH-SYSY cell line, mouse neuroblastoma Neuro2A

rin Was immunoprecipitated. Right Panel: The same as

described for the Left Panel, except for that the solubiliZed
samples Were immunoprecipitated With anti-Kalirin and
immunoblotted With anti iNOS. (C) Autoradiogram of anti

30

either With pcDNA3 carrying the iNOS cDNA (denoted as
iNOS) or empty pcDNA3. Some of the cells Were also treated
With LPS for 16 h to induce iNOS. In addition, RNAs Were
35

equal volume (Left Panel) or equal CPM (Right Panel) of
individual tubes Was electrophoresed and autoradiographed.
The radioactivities of individual tubes Were plotted (inset
graph of the Left Panel). Immunoblots of Kalirin and iNOS
(as shoWn in A) are combined to shoW the band positions of
Kalirin and iNOS.
FIG. 6A-F shoWs identi?cation of Kalirin domain respon
sible for attenuation of iNOS. (A) Effect of Kalirin plasmid on
iNOS. The AtT-20 cell line stably expressing iNOS Was tran

siently transfected With increasing amounts of the pcDNA4
carrying the Kalirin-7 cDNA and assayed for iNOS. The cells

cell line, and rat glioma C6 cell line. The cell lines Were stably
transfected either With pcDNA4 carrying the Kalirin-7 cDNA
(denoted as Kalirin) or With empty pcDNA4. The tWo types of
stable cell lines Were established and transiently transfected

Kalirin immunoprecipitate of AD Hippocampus sample. The
pooled AD Hippocampal sample Was immunoprecipitated
With anti-Kalirin and radio-iodinated. Free iodine Was
removed by fractionation on a Sephadex G-150 column. An

(A) Induction of iNOS by LPS and iNOS plasmid and attenu
ation of iNOS by Kalirin in mouse AtT20, human neuroblas

extracted from the cells and used to produce the cDNA frag
ments for iNOS, Kalirin and GAPDH by RT-PCR as shoWn

underneath the bar graph. (B) Attenuation iNOS by NOS
inhibitors. The stable cell lines described inA Were assayed
for iNOS With or Without a speci?c inhibitor for iNOS (Cana
40

vanine) or general inhibitor for NOS (L-NAME). (C) Effect
of A[31-42. Stable cell lines described inA Were treated With

LPS plus A[31-42 for 16 h and assayed for iNOS.
FIG. 8 shoWs the upstream regulatory sequence (SEQ ID
NO:51) ofkalirin 7.
45

DETAILED DESCRIPTION

Were solubiliZed and 10% of the solubiliZed samples Were

immunoblotted With anti-Kalirin (upper gel). The rest of the
solubiliZed samples Were immunoprecipitated With anti-Ka
lirin and immunoblotted With anti-iNOS (loWer gel). To test
for a potential toxic effect of the Kalirin plasmid on the cells,
the cells Were transiently co-transfected With increasing
amounts of the pcDNA4 carrying Kalirin-7 cDNA plus a
constant amount of the pRL-TK vector encoding Renilla

50

ence to “a protein” includes a plurality of such proteins and
reference to “the cell” includes reference to one or more cells

knoWn to those skilled in the art, and so forth.

luciferase, and assayed for iNOS (bar) and luciferase (dotted
line). (B) Kalirin comprises a Sec14p-like putative lipid bind
ing domain, nine spectrin-like repeats, tandem DH and pleck
strin homology (PH) domain. (C) A continuous series of
Kalirin domains (D1, D2, D3, D4, DH and PH shoWn in SC)

55

Was subcloned into pcDNA4. When AtT-20 cells stably
expressing iNOS Were transiently transfected With various

60

lent to those described herein can be used in the practice of the

disclosed methods and compositions, the exemplary meth
ods, devices and materials are described herein.

The publications discussed above and throughout the text
are provided solely for their disclosure prior to the ?ling date
of the present application. Nothing herein is to be construed

Was most notably attenuated by D2. “Mix” stands for the
mixture of the domain plasmids and “Full” stands for the
Was further divided into 19 overlapping sections, each com
prising 33 amino acids. The cDNAs for the 19 sections Were

Unless de?ned otherWise, all technical and scienti?c terms
used herein have the same meaning as commonly understood
to one of ordinary skill in the art to Which this disclosure

belongs. Although methods and materials similar or equiva

pcDNA4 carrying the individual domains of Kalirin-7, iNOS

plasmid encoding the full length Kalirin-7. (D) D2 domain

As used herein and in the appended claims, the singular
forms “a,” “and,” and “the” include plural referents unless the
context clearly dictates otherWise. Thus, for example, refer

as an admission that the inventors are not entitled to antedate
65

such disclosure by virtue of prior disclosure.
AlZheimer’s disease (AD) is the most prevalent adult
dementing disorder. The pathological characteristics of AD

US 7,867,978 B2
5

6

are brain atrophy, amyloid plaques and neuro?brillary tangle

negatively regulates iNOS enZyme activity. The inhibition is

formation, and neuron and synapse loss. AD is related to a

number of factors including the presence of amyloid-[3 pep
tide, presenilins 1 and 2, NO and iNOS production and activ

attributed primarily to the ~33 amino acid domain around
K6l7-H649 (SEQ ID NO:3 or SEQ ID NO:2 from amino acid
617 to 649; see FIG. 6), demonstrating that Kalirin 7 is

ity (respectively), and apolipoprotein E (ApoE) isoforms,

responsible for the negative regulation of iNOS. These results

impacting gene expression inAD. The gene expression analy
sis provided herein of hippocampal and cerebellar specimens

indicate that the elevated NO level in the AD hippocampal

specimens is closely correlated With the enhanced iNOS
activity and to the under-expression of Kalirin-7. It also pro
vides a simple explanation for the correlation of the loW level
of neuronal Kalirin and the high activity of iNOS in AD

of 19 AD in comparison to 15 age- and sex-matched control

brains shoWs many AD-associated differentially expressed
genes and expressed sequence tags. Among them is the gene
Kalirin, speci?cally the Kalirin-7 isoform.

(FIGS. 2 and 3A) that is expressed throughout neuronal and

Inducible nitric oxide (iNOS) and NO have been shoWn to

non-neuronal cells as Well as aberrant NOS expression inAD.

be important in AD. High iNOS activity cannot be explained
by the expression levels of iNOS mRNA and protein in AD
and control hippocampi. For example, iNOS knockout mice
are protected from the AD phenotype. Amyloid-[3 induces

Individual specimens shoW signi?cant variations in the
expression levels of NOS, Which could have contributed,
along With variant locations of small specimens excised from
the hippocampus, to diverse observations on aberrant NOS

expression in AD.
The disclosure established the under-expression of Kali

iNOS activity and elevated NO levels are globally observed in

AD hippocampi compared to normal tissues. HoWever, iNOS
protein expression and its enzymatic activity do not shoW a

correlation (FIGS. 3A and 3B), suggesting that iNOS activity
is regulated through a mechanism other than expression lev
els. The importance of other regulatory mechanism is further
underscored by the fact that NO levels vary dramatically
among various cell lines (FIG. 7). The iNOS activity is ~10
fold higher in AtT-20 cells than other cell lines described in
FIG. 7 and ~100 fold higher than HEK293 cells stably
expressing iNOS. The under expression of Kalirin-7 correlate
With elevated iNOS activity in AD hippocampi, Which is
higher in all of the 19 AD hippocampal specimens compared
With all of the tissue specimens of the 15 control hippocampi,

20

rin-7 in AD hippocampus and its role in AD that includes the
complex formation With iNOS and deleterious NO in AD

brain, further damaging the negative regulation of iNOS
activity. The data demonstrate that the regulation of Kalirin 7
expression and decrease in Kalirin-7 expression in AD brain
activity in the hippocampus contributes to AD development
25

through iNOS and NO production.

30

form of Kalirin in the adult brain, Kalirin-7, is signi?cantly
diminished in AD patient brains, both at the mRNA and
protein levels. The disclosure further demonstrates a complex
of Kalirin-7 With iNOS, With less Kalirin-7 being consumed

The disclosure demonstrates that the most prevalent iso

19 AD cerebella and 15 control cerebella.

in this complex With iNOS in AD brain extracts than in

Kalirin-7 is a cytoplasmic protein of >1,660 amino acids
and plays crucial regulatory roles in groWth and maintenance

control brain extracts. Since the amyloidogenic peptide A
[31 -42 induces iNOS in brain and Kalirin normally inactivates

of neurons. Kalirin comprises over a doZen alternate splicing

forms, all primarily expressed in the brain, particularly in the
hippocampus With the most intense expression in neurons;
tissue culture studies demonstrate that Kalirin isoforms play
crucial roles in neuronal stability and groWth. Kalirin is
essential for the groWth and maintenance of hippocampal
pyramidal neuron dendrites and dendritic spines. Originally
cloned from rat and human brains, Kalirin plays a role in the

35

production of deleterious NO in AD brain, further damaging
the AD brain.

Accordingly, the disclosure provides methods and compo
40

huntingtin dependent Ras-related signal pathWay and patho

In one aspect, the disclosure provides a method of allevi

ating senile dementia (e.g., AD) comprising contacting a

rodegenerative disease that is frequently associated With
45

proteins, including the cytoplasmic domain of peptidylgly
cine ot-amidating monooxygenase, huntingtin-associated
neurodegenerative disorders and other diseases. The regula
tory effect of the Kalirin domain and Kalirin have therapeutic
potential in controlling iNOS activity and thus limit AD
development. In addition to Kalirin-7, genes for voltage
gated Ca2+ channel y-subunit 3 and visinin-like protein 1 (a

50

Ca2+ sensor protein) are under-expressed, Whereas inositol

55

homeostasis. In contrast to the differentially expressed genes,
housekeeping genes such as ribosomal protein genes are not
60

Human Kalirin-7 associates With iNOS in the human hip

pocampus (FIG. 5) and negatively regulates iNOS enZyme
activity in neuronal cell lines (FIG. 7), consistent With the
system. Furthermore, Kalirin-7 ssociates With inducible NO

synthase (iNOS) protein in the human hippocampus and

The effectiveness of the method of the disclosure in alle
viating senile dementia can be demonstrated using recog
niZed animal models of AD as Well as in vitro assays that

1,4,5-triphosphate 3-kinase B is over-expressed. Collec
tively, these differential expression patterns can impair Ca2+

observation that rat Kalirin interacts With mouse iNOS, inhib
its the dimeriZation of iNOS and its activity in the mouse cell

subject With an active fragment of kalirin. In one aspect, the
senile dementia is associated With elevated levels of NO. In
another aspect, the senile dementia is associated With elevated

iNOS activity.

protein 1 and iNOS. HoWever, there are no prior reports
demonstrating a direct role for any Kalirin isoform in any

affected by AD.

sitions for the treatment of dementia caused by decreased
kalirin, increased iNOS activity, and increased NO in neu
rons. Furthermore, the disclosure provides methods of diag
noses and prognoses of dementia.

genesis of Huntington’s disease, an autosomal dominant neu
dementia. Kalirin interacts With a number of cytoplasmic

some iNOS in brain, the data demonstrate that the decrease in
Kalirin-7 expression in AD brain contributes to the increased

65

detect changes in iNOS or NO in a biological sample upon
exposure to a test agent (e.g., an active fragment of kalirin).
As used herein, the term “inhibiting senile dementia” or
“alleviating senile dementia” refers to any diminution in the
severity of senile dementia. In a human subject, an active

fragment of kalirin or kalirin therapy reduces the severity of
senile dementia such that the subj ect’s suffering or dementia
(e.g., duration or severity) is diminished and quality of life is
improved. Alternatively, the dementia of a subject may be
reduced but may not be readily apparent, under these circum
stances, a reduction in NO, iNOS or A6 peptides may be
indicative of a reduction in the severity of the disorder.
For use in alleviating senile dementia in a human subject,
an active fragment of human kalirin such as, for example,
SEQ ID NO:3 is used. HoWever, an active fragment derived
from another mammalian kalirin polypeptide is useful in

US 7,867,978 B2
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alleviating senile dementia according to the method of the
disclosure. Thus, for example, an active fragment of mouse
kalirin, rat kalirin, guinea pig kalirin or bovine kalirin can be
useful in alleviating senile dementia in a subject. As set forth
above, the amino acid sequence of an active fragment of
kalirin (SEQ ID NO:3), Which corresponds to amino acids
617-649 of kalirin, is Well conserved among other species. A
peptide useful in the methods of the disclosure can include,

limited to, partial forms, isoforms, variants, precursor forms,
the full length protein, fusion proteins containing the
sequence or fragments of any of the above, from human or any

other species. Protein homologs or orthologs Which Would be
apparent to one of skill in the art are included and contem

plated by the disclosure. It is also contemplated that the term
refers to proteins isolated from naturally occurring sources of
any species such as genomic DNA libraries as Well as geneti

cally engineered host cells comprising expression systems, or
produced by chemical synthesis using, for instance, auto

for example, SEQ ID NOS:3 through 26 (see TABLE above).
“Dementia” and “senile dementia” refer to a decline in
cognitive function due to deterioration of neurons and neu

mated peptide synthesizers or a combination of such meth

ronal signaling beyond What is expected due to normal aging.

ods. Means for isolating and preparing such polypeptides are

Cognitive areas that are effected include memory, attention,

Well understood in the art.
The term “sample” as used herein, is used in its broadest

language and problem solving. An affected persons can be
disoriented in time and place. Symptoms of dementia can be

sense. A biological sample from a subject may comprise

blood, urine, brain tissue, primary cell lines, immortalized

classi?ed as either reversible or irreversible depending upon
the etiology of the disease. Less than 10% of all dementias are
reversible. Senile dementia can be caused by a number of
diseases and disorder. For example, senile dementia can be

caused by Alzheimer’s disease, vascular dementia (also
knoWn as multi-infarct dementia), including BinsWanger’s
disease, dementia With LeWy bodies (DLB), Alcohol Induced

20

expression pro?ling using, for example, conventional glass
chip microarray technologies such as Affymetrix chips, RT

Persisting Dementia, Frontotemporal lobar degeneration
(FTLD), including Pick’s disease, Frontotemporal dementia
(or frontal variant FTLD), Semantic dementia (or temporal

PCR or other conventional methods. In one aspect, a sample

comprises cerebral spinal ?uid and/or neurological tissue.
25

variant FTLD), and progressive non-?uent aphasia, to name a
feW. In some aspect, the senile dementia can be attributed to

the activity of induced nitric oxide synthase (iNOS) and the
formation ofA[3 secretions. One such pathological conditions
associated with A6 secretions is Alzheimer’s Disease (AD).
“Pathological conditions associated with A6 secretion”
include conditions associated With abnormalities in the APP
pathWay, including but not limited to, modi?ed APP metabo
lism or processing of components involved in the APP path
Way, for example, abnormal ot-, [3-, or y-secretase activity,
and/ or A6 secretion Which may be characterized by the for

cell lines, or other biological material With Which protein
activity or gene expression may be assayed. A biological
sample may include, for example, blood, tumors or other
specimens from Which total RNA may be puri?ed for gene

30

A “therapeutically effective amount” is the amount of a
polypeptide or polynucleotide of the disclosure su?icient to
treat, prevent or ameliorate pathological conditions associ
ated With dementia and/or nitric oxide and/or iNOS produc
tion or activity.
A “subject” refers to any human or nonhuman mammal.

The disclosure provides methods and compositions useful
in alleviating senile dementia (e.g., AD) resulting from or
associated With NO activity or production and/ or a reduction
35

in kalirin 7 production or expression.
The method of the disclosure can be useful in alleviating
senile dementia regardless of the etiology. For example, a

mation of insoluble amyloid deposits (senile plaques), the

method of the disclosure can be used to alleviate senile

major component of Which is the 40-42 amino acid amyloid
beta (AB) peptide, a proteolytic product of the amyloid pre
cursor protein (APP). Such conditions include Alzheimer’s

dementia resulting from a decrease in kalirin expression,
iNOS overexpression, NO production and the like.
An agonist is any molecule that improves the activity of a

40

Disease as Well as other conditions characterized by degen
eration and eventual death of neurons in brain clusters con

trolling memory, cognition and behavior. Such conditions
may also include, but are not limited to, Parkinson’ s Disease,

tauopathies, prion diseases, frontotemporal dementia, stria
tonigral degeneration, LeWd body dementia, Huntington’s

45

be capable of interacting With iNOS.

disease, Pick’s disease, amyloidosis, and other neurodegen
erative disorders associated With excess AB production.
A “polynucleotide”, as used herein, refers to an oligonucle
otide, nucleotide or polynucleotide, and fragments or por
tions thereof, and to DNA or RNA of genomic or synthetic
origin that may be single or double stranded, and represent the

In one embodiment, a kalirin agonists may be a heterolo
gous kalirin polypeptide or polynucleotide or a kalirin-de
50

sense or antisense strand.

A “cDN ” refers to DNA that is complementary to a

portion of messenger RNA (mRNA) sequence and is gener
ally synthesized from an mRNA preparation using reverse

different molecule; e.g., a hormone, Which acts as an agonist
When it binds to its receptor, thus triggering a biochemical
response, or the production of a heterologous molecule that
increase the biological activity in cell. associated With a simi
lar homogenous molecule. For example, a kalirin agonist can

55

transcriptase.

rived peptide. As used herein, the term “active fragment of
kalirin” is synonymous With “kalirin-derived peptide” and
“kalirin”. A peptide useful in the methods of the disclosure
can be derived from kalirin (see, e.g., SEQ ID NO:2). More

particularly, the kalirin-derived peptide comprises a fragment
of SEQ ID NO:2 containing the sequence ARHLEVRIQD
FVRRVEQRKLLLDMSVSFHTH (residues 3-33 of SEQ ID
NO: 3) and peptides having from about 70%, 80%, 85%,
90%, 95%, 98% or 99% identity to the foregoing sequence
(including the sequences as set forth in the Table beloW (SEQ

The individual proteins/polypeptides referred to herein
include any and all forms of these proteins including, but not

ID NOsz3-26).

Name

GI

human

118093831 673
47933903

1 KAARHLEVRIQDFVRRVEQRKLLLDMSVSFHTH
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An NO inhibiting activity of kalirin can be localized to an 40 function of the number of identical positions shared by the
sequences, taking into account the number of gaps, and the
approximate 33 amino acid segment of kalirin. An active
length of each gap, Which need to be introduced for optimal
fragment of Kalirin has about 25 amino acids to about 80
alignment of the tWo sequences.
amino acids, but can include the full-length of Kalirin (e.g.,
The comparison of sequences and determination of percent
SEQ ID NO:2). Typically, an active fragment of kalirin has
about 28 amino acids to about 37 amino acids and, more 45 identity betWeen tWo sequences can be accomplished using a
commonly, about 30 amino acids to about 35 amino acids. A
mathematical algorithm. In a one embodiment, the percent
33-mer peptide corresponding to amino acids 617 to 649 of
identity betWeen tWo amino acid sequences is determined
using the GAP program in the GCG softWare package (avail
kalirin (SEQ ID N012) inhibits NO production and/ or iNOS
able at http:~~WWW.gcg.com), using either a Blossom 62
activity.
To determine the percent identity of tWo amino acid 50 matrix or a PAM250 matrix, and a gap Weight of l6, l4, l2,
l0, 8, 6, or 4 and a length Weight of l, 2, 3, 4, 5, or 6. In yet
sequences or of tWo nucleic acid sequences, the sequences are
another preferred embodiment, the percent identity betWeen
aligned for optimal comparison purposes (e.g., gaps can be
tWo nucleotide sequences is determined using the GAP pro
introduced in one or both of a ?rst and a second amino acid or
gram in the GCG softWare package (available at http:~~WWW.
nucleic acid sequence for optimal alignment and non-ho
mologous sequences can be disregarded for comparison pur 55 gcg.com), using a NWSgapdna.CMP matrix and a gap Weight
of40, 50, 60, 70, or 80 and a length Weight of l, 2, 3, 4, 5, or
poses). In a one embodiment, the length of a reference
6.
sequence aligned for comparison purposes is at least 30%, at
The nucleic acid and protein sequences of the disclosure
least 40%, at least 50%, at least 60%, but typically at least
can further be used as a “query sequence” to perform a search
70%, 80%, or 90% of the length of the reference sequence.
The amino acid residues or nucleotides at corresponding
amino acid positions or nucleotide positions are then com

60

formed using the NBLAST and XBLAST programs (version
2.0) ofAltschul, et al. (1990) J. Mol. Biol. 2151403-10.

pared. When a position in the ?rst sequence is occupied by the
same amino acid residue or nucleotide as the corresponding

position in the second sequence, then the molecules are iden
tical at that position (as used herein amino acid or nucleic acid
“identity” is equivalent to amino acid or nucleic acid “homol
ogy”). The percent identity betWeen the tWo sequences is a

against public databases to, for example, identify other family
members or related sequences. Such searches can be per

As used herein, the term “amino acid” refers to one of the
65

tWenty naturally occurring amino acids, including, unless
stated otherWise, L-amino acids and D-amino acids. The term
amino acid also refers to compounds such as chemically

US 7,867,978 B2
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modi?ed amino acids including amino acid analogs, naturally

supra (1991)). A chimeric peptide-pharmaceutical that has
increased biological stability or increased permeability to the

occurring amino acids that are not usually incorporated into
proteins such as norleucine, and chemically synthesized com
pounds having properties knoWn in the art to be characteristic
of an amino acid, provided that the compound can be substi
tuted Within a peptide such that it retains its biological activ
ity. For example, glutamine can be an amino acid analog of

blood-brain barrier, for example, also can be useful in the
method of the disclosure.
As used herein, the term “a senile dementia alleviating

asparagine, provided that it can be substituted Within an active

tia, Whether by alleviating senile dementia or by inhibiting the

fragment of kalirin that retains its activity in alleviating senile

onset of senile dementia or reducing causative agents of
dementia (e.g., elevated NO). An effective amount to be
administered systemically on a daily basis depends on the
body Weight of the subject. Typically, an effective amount to
be administered systemically on a daily basis is about 0.1
ug/kg to about 1000 ug/kg. More commonly, an effective

amount” or “effective amount” means the amount of a kalirin

polypeptide useful for causing a diminution in senile demen

dementia or other iNOS or NO associated disorders. An
amino acid also can be an amino acid mimetic, Which is a

structure that exhibits substantially the same spatial arrange
ment of functional groups as an amino acid but does not

necessarily have both the alpha-amino and alpha-carboxyl
groups characteristic of an amino acid. Other examples of
amino acids and amino acids analogs are listed in Gross and

Meienhofer, The Peptides: Analysis, Synthesis, Biology,

amount to be administered systemically on a daily basis is
about 10 ug/kg to about 100 ug/kg. An effective amount of a
peptide for alleviating or inhibiting the onset of dementia can

Academic Press, Inc., NeW York (1983).

be determined empirically using methods Well knoWn to

A kalirin polypeptide or active fragment thereof can be
isolated or synthesiZed using methods Well knoWn in the art.
Such methods include recombinant DNA methods and

those in the art.
20

chemical synthesis methods for production of a peptide.
Recombinant methods of producing a peptide through
expression of a nucleic acid sequence encoding the peptide in
a suitable host cell are Well knoWn in the art and are described,

polypeptide (e.g., an active fragment of kalirin) intrave

nously, intramuscularly, intradermally, subcutaneously,
intracranially, intracerebrospinally, topically, orally, trans
25

for example, in Sambrook et al., Molecular Cloning: A Labo
ratory Manual, 2nd Ed., Vols. 1 to 3, Cold Spring Harbor

phosphate buffered saline (PBS).

Alternatively a kalirin polypeptide or active fragment can
30

peptide synthesis method of Merri?eld et al., J. Am. Chem.
Soc. 8522149 (1964). Standard solution methods Well known
in the art also can be used to synthesiZe a peptide useful in the

disclosure (see, for example, BodansZky, Principles of Pep
tide Synthesis, Springer-Verlag, Berlin (1984) and Bodan
sZky, Peptide Chemistry, Springer-Verlag, Berlin (1993)). A
neWly synthesiZed peptide can be puri?ed, for example, by
high performance liquid chromatography (HPLC), and can

35

be characterized using, for example, mass spectrometry or

amino acid sequence analysis.

40

It is understood that modi?cations can be made to a kalirin

polypeptide or active fragment Without destroying its biologi
cal function. Thus, a modi?cation of an active fragment of
kalirin that does not destroy its ability to alleviate senile
dementia is Within the de?nition of a kalirin polypeptide. A
modi?cation can include, for example, an addition, deletion,

50

55

substitution or deletion of lysine can increase the stability of
degradation. The substitution or deletion of a lysine residue
confers increased resistance to trypsin-like proteases, as is
60

A useful modi?cation also can be one that promotes pep
tide passage across the blood-brain barrier, such as a modi?

Banks et al., Peptides 13:1289-1294 (1992) and Pardridge,

fusion molecule. For example, transduction can be achieved
in accord With the disclosure by use of a protein sequence
such as an HIV TAT protein or fragment thereof that is

tein can be the Antennapedia homeodomain or the HSV VP22

sequence, the N-terminal fragment of a prion protein or suit
able transducing fragments thereof such as those knoWn in the
art.

an active fragment of kalirin by protecting against peptide

cation that increases lipophilicity or decreases hydrogen
bonding. For example, a tyrosine residue added to the C-ter
minus of a kalirin polypeptide can increase hydrophobicity
and permeability to the blood-brain barrier (see, for example,

methods and compositions that combine the use of PTDs such
as TAT and poly-Arg, With an active fragment of kalirin to
promote uptake into a cell either in vitro or in vivo.
In general, the transduction domain of the fusion molecule
can be nearly any synthetic or naturally-occurring amino acid

covalently linked at the N-terminal or C-terminal end to an

is one that confers, for example, increased stability. For

Well knoWn in the art (Partridge, supra (1991)).

by disruption of the endosomal vesicle. Examples of PTDs
include AntHD, TAT, VP22, cationic prion protein domains
and functional fragments thereof. The disclosure provides

active fragment of kalirin. Alternatively, the transducing pro

senile dementia can be assayed using an animal model of
senile dementia.
A particularly useful modi?cation of a kalirin polypeptide
example, incorporation of one or more D-amino acids or

In one aspect, the method of administration comprises a

fusion polypeptide comprising a transduction domain (e.g., a
PTD) and an active fragment of kalirin. PTDs are typically
cationic in nature. These cationic protein transduction
domains track into lipid raft endosomes carrying With them
their linked cargo and release their cargo into the cytoplasm

sequence that can transduce or assist in the transduction of the
45

or substitution of amino acid residues (e.g., 1 to 10); a sub
stitution of a compound that mimics amino acid structure or
function; and addition of chemical moieties such as amino or

acetyl groups. The activity of a modi?ed peptide in alleviating

dermally, transmucosally, or intranasally. A pharmaceutically
acceptable carrier of Well knoWn type can be administered
With a kalirin polypeptide. Such carriers include, for example,

Laboratory Press, NeW York (1989).
be chemical synthesiZed, for example, by the solid phase

The disclosure provides methods of alleviating dementia
(e.g., AD) by administering an effective amount of a kalirin

The type and siZe of the PTD Will be guided by several
parameters including the extent of transduction desired.
PTDs Will be capable of transducing at least about 20%, 25%,
50%, 75%, 80% or 90% of the cells of interest, more typically
at least about 95%, 98% and up to, and including, about 100%
of the cells. Transduction e?iciency, typically expressed as
the percentage of transduced cells, can be determined by
several conventional methods.
In one aspect, a PTD useful in the methods and composi

tions of the disclosure comprise a peptide featuring substan
tial alpha-helicity. It has been discovered that transduction is
65

optimiZed When the PTD exhibits signi?cant alpha-helicity.
In another embodiment, the PTD comprises a sequence con

taining basic amino acid residues that are substantially

US 7,867,978 B2
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aligned along at least one face of the peptide. A PTD domain
of the disclosure may be a naturally occurring peptide or a

fusion polypeptides or chimeric proteins comprising one or
more PTDs linked to an active fragment of kalirin may be
linked by a peptide linker. Each of the several domains may be

synthetic peptide.

directly linked or may be separated by a linker peptide. The
domains may be presented in any order Additionally, the
fusion polypeptides may include tags, e.g., to facilitate iden
ti?cation and/ or puri?cation of the fusion polypeptide, such

In yet another embodiment, the PTD domain comprises a

peptide represented by the folloWing general formula:
B1iXliX2iX3iB2iX4iX5iB3 (SEQ ID N0:27)
Wherein B 1, B2, and B3 are each independently a basic amino
acid, the same or different; andX 1, X2, X3, X4 and X5 are each
independently an alpha-helix enhancing amino acid the same
or different. In another embodiment, the PTD domain is rep

resented by the folloWing general formula: B1iX1iX2i
B2iB3iX3iX4iB4 (SEQ ID N0:28) Wherein B1, B2, B3,

as a 6xHIS tag (SEQ ID NO: 52).
Peptide linkers that can be used in the fusion polypeptides
Will typically comprise up to about 20 or 30 amino acids,
commonly up to about 10 or 15 amino acids, and still more
often from about 1 to 5 amino acids. The linker sequence is

and B4 are each independently a basic amino acid, the same or

generally ?exible so as not to hold the fusion molecule in a

different; and X1, X2, X3, and X4 are each independently an

single rigid conformation. The linker sequence can be used,

alpha-helix enhancing amino acid the same or different.

e.g., to space the PTD domain from an active fragment of

Additionally PTD domains comprise basic residues, e.g.,
lysine (Lys) or arginine (Arg), and further including at least

kalirin. For example, the peptide linker sequence can be posi
tioned betWeen the protein transduction domain and the kali

one proline (Pro) residue suf?cient to introduce “kinks” into
the domain. Examples of such domains include the transduc
tion domains of prions. For example, such a peptide com

rin peptide, e.g., to provide molecular ?exibility. The length
of the linker moiety is chosen to optimiZe the biological
activity of the polypeptide comprising a PTD domain fusion

20

prises KKRPKPG (SEQ ID N0:29).

construct and can be determined empirically Without undue

In another embodiment the PTD is cationic and consists of
betWeen 7 and 10 amino acids and has the formula

GGGGS (SEQ ID N032), (GGGGS)N (SEQ ID N033),

KXIRXZXl (SEQ ID N030) Wherein X1 is R or K and X2 is
any amino acid. An example of such a peptide comprises

experimentation. Examples of linker moieties are -Gly-Gly-,

25

RKKRRQRRR (SEQ ID N031).
Additional transducing domains in accord With this inven
tion include a TAT fragment that comprises at least amino
acids 49 to 56 of TAT up to about the full-length TAT

are described, for example, in Huston et al., Proc. Nat’lAcad.

sequence. A TAT fragment may include one or more amino 30

acid changes su?icient to increase the alpha-helicity of the
fragment. In some instances, the amino acid changes intro
duced Will involve adding a recogniZed alpha-helix enhanc
ing amino acid. Alternatively, the amino acid changes Will
involve removing one or more amino acids from the TAT

Sci. 8515879, 1988; WhitloW et al., Protein Engineering
6:989, 1993; and NeWton et al., Biochemistry 35:545, 1996.
Other suitable peptide linkers are those described in US. Pat.

Nos. 4,751,180 and 4,935,233, Which are hereby incorpo
rated by reference.
35

fragment the impede alpha helix formation or stability. In a
more speci?c embodiment, the TAT fragment Will include at

An isolated polynucleotide of the disclosure include DNA
and RNA in both single-stranded and double-stranded form,
as Well as the corresponding complementary sequences.

DNA includes, for example, cDNA, genomic DNA, chemi
cally synthesiZed DNA, DNA ampli?ed by PCR, and combi

least one amino acid substitution With an alpha-helix enhanc

ing amino acid. Typically the TAT fragment Will be made by

standard peptide synthesis techniques although recombinant

GKSSGSGSESKS (SEQ ID N034), GSTSGSGKSSEGKG
(SEQ ID N035), GSTSGSGKSSEGSGSTKG (SEQ ID
N036), GSTSGSGKPGSGEGSTKG (SEQ ID N037), or
EGKSSGSGSESKEF (SEQ ID N038). Linking moieties

nations thereof. The polynucleotides of the disclosure include
40

full-length genes or cDNA molecules as Well as a combina

DNA approaches may be used in some cases.

tion of fragments thereof. The polynucleotides of the disclo

Additional transduction proteins (PTDs) that can be used
in the compositions and methods of the disclosure include the
TAT fragment in Which the TAT 49-56 sequence has been

sure are typically derived from human sources, but the dis
closure includes those derived from non-human species, as

modi?ed so that at least tWo basic amino acids in the sequence

are substantially aligned along at least one face of the TAT
fragment. Illustrative TAT fragments include at least one
speci?ed amino acid substitution in at least amino acids 49-56
of TAT Which substitution aligns the basic amino acid resi
dues of the 49-56 sequence along at least one face of the
segment and typically the TAT 49-56 sequence.

Well. In one aspect, a polynucleotide of the disclosure com
45

NO:2; (iii) a polynucleotide encoding an active fragment of
SEQ ID NO:2; (iv) a polynucleotide encoding SEQ ID N03
50

otide that hybridiZes to any of (i-vi) under highly stringent

transducing proteins include parts of at least tWo different

ment thereof.

transducing proteins. For example, chimeric transducing pro
55

e.g., one from HIV-1 and the other from HIV-2 or one from a

prion protein and one from HIV.
PTDs can be linked or fused With an active fragment of
kalirin. It Will be understood that the PTD may be fused to an
active fragment of kalirin or the coding sequences for a PTD

60

and the coding sequence for an active fragment of kalirin may
be operably linked such that upon expression in a suitable
recombinant cell a fusion polypeptide is provided.

As noted, components of the fusion polypeptides disclosed
herein, e.g., a PTD and an active fragment of kalirin, can be

25 or 26; (v) a polynucleotide of any one of (i-iv) Wherein T
can be U; (vi) a complement of any of (i-v); and a polynucle
conditions and encodes a kalirin polypeptide or active frag

Also included are chimeric PTD domains. Such chimeric

teins can be formed by fusing tWo different TAT fragments,

prises (i) a polynucleotide comprising SEQ ID N0:1; (ii) a
polynucleotide encoding a polypeptide comprising SEQ ID

65

An “isolated polynucleotide” is one that has been separated
from adjacent genetic sequences present in the genome of the
organism from Which the polynucleotide Was isolated, in the
case of polynucleotides isolated from naturally-occurring
sources. In the case of polynucleotides synthesiZed enZymati
cally from a template or chemically, such as PCR products,
cDNA molecules, or oligonucleotides for example, it is
understood that the polynucleotides resulting from such pro
cesses are isolated polynucleotides. An isolated polynucle
otide refers to a polynucleotide in the form of a separate
fragment or as a component of a larger polynucleotide con
struct. In one embodiment, isolated polynucleotides are sub

organiZed in nearly any fashion provided that the fusion

stantially free from contaminating endogenous material. The

polypeptide has the function for Which it Was intended. The

polynucleotide typically is derived from DNA or RNA iso

US 7,867,978 B2
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lated at least once in substantially pure form and in a quantity

and has at least 60% sequence identity (at least 70%, at least
75%, at least 80%, at least 85%, at least 90%, at least 95%, at
least 97.5%, or at least 99%, and most preferably at least
99.5%) With the polynucleotide of the disclosure to Which it
hybridizes, Where sequence identity is determined by com

or concentration enabling identi?cation, manipulation, and
recovery of its component nucleotide sequences by standard
biochemical methods (such as those outlined in Sambrook et

al., Molecular Cloning: A Laboratory Manual, 2nd sed., Cold
Spring Harbor Laboratory, Cold Spring Harbor, NY. (1989)).

paring the sequences of the hybridizing polynucleotides

Such sequences are provided and/or constructed in the form

When aligned so as to maximize overlap and identity While

of an open reading frame uninterrupted by internal non-trans
lated sequences, or introns, that are typically present in
eukaryotic genes. Sequences of non-translated DNA can be

minimizing sequence gaps.
The disclosure also provides genes corresponding to the
polynucleotide sequences disclosed herein. “Corresponding
genes” or “corresponding genomic polynucleotides” are the

present 5' or 3' from an open reading frame, Where the same

do not interfere With manipulation or expression of the coding

regions of the genome that are transcribed to produce the
mRNAs from Which cDNA polynucleotide sequences are

region.
The disclosure also includes polynucleotides that hybrid
ize under moderately stringent conditions, and more typically
under highly stringent conditions, to the complement of poly

derived and may include contiguous regions of the genome
necessary for the regulated expression of such genes. Corre

nucleotides that encode the Kalirin polypeptides or active

coding sequences, 5' and 3' untranslated regions, alternatively
spliced exons, introns, promoters, enhancers, and silencer or

sponding genes may therefore include but are not limited to

fragment described herein (e.g., SEQ ID NO:2 or 3, respec

tively). The basic parameters affecting the choice of hybrid
ization conditions and guidance for devising suitable condi

20

suppressor elements. The corresponding genes can be iso
lated in accordance With known methods using the sequence

tions are set forth by Sambrook, 1., E. F. Fritsch, and T.

information disclosed herein, for example, for designing

Maniatis (1989, Molecular Cloning: A Laboratory Manual,
Cold Spring Harbor Laboratory Press, Cold Spring Harbor,

probes or PCR primers. Such methods include the preparation
of probes or primers from the disclosed sequence information
for identi?cation and/or ampli?cation of genes in appropriate

N.Y., chapters 9 and 11; and Current Protocols in Molecular
Biology, 1995, F. M. Ausubel et al., eds., John Wiley & Sons,
Inc., sections 2.10 and 6.3 6.4), and can be readily determined
by those having ordinary skill in the art based on, for example,
the length and/ or base composition of the DNA. One Way of

25

genomic polynucleotide that has been separated from the
adjacent genomic sequences present in the genome of the
organism from Which the genomic polynucleotide Was iso

achieving moderately stringent conditions for ?lter-bound
target DNA involves the use of a preWashing solution con

30

taining 5><SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybrid
ization buffer of about 6><SSC, and a hybridization tempera
ture of about 68° C. (or other similar hybridization solutions,
such as one containing about 50% formamide, With a hybrid

ization temperature of about 42° C.), and Washing conditions
ofabout 60° C., in 0.5><SSC, 0.1% SDS. “SSC” (1 x) is 0.15 M

genomic libraries or other sources of genomic materials. An
“isolated gene” or “an isolated genomic polynucleotide” is a
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lated.
The isolated polynucleotide of the disclosure may be oper
ably linked to an expression control sequence such as that in
the pDC412 or pDC314 vectors, or the pMT2 or pED expres
sion vectors disclosed in Kaufman et al., Polynucleotides
Res. 19, 4485 4490 (1991); and PouWels et al. Cloning Vec

tors: A Laboratory Manual, Elsevier, N.Y., (1985), in order to

produce the polypeptide recombinantly. Many suitable

NaCl, 0.015 M Na citrate, pH 7.0. Generally, highly stringent
conditions are de?ned as hybridization conditions as above,

expression control sequences are knoWn in the art. General

but With Washing at approximately 68° C., 0.2><SSC, 0.1%
SDS. If desired, SSPE (1><SSPE is 0.15M NaCl, 10 mM
NaH2PO4, and 1.25 mM EDTA, pH 7.4) can be substituted
for SSC in the hybridization and Wash buffers, and the SDS

methods of expressing recombinant polypeptides are also
knoWn, such as those described in R. Kaufman, Methods in
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Enzymology 185, 537 566 (1990). As used herein “operably
linked” means that the polynucleotide of the disclosure and an
expression control sequence are situated Within a construct,
vector, or cell in such a Way that the polypeptide encoded by

can be omitted from any of the above the buffers Without

affecting the stringency. Washes are performed for 15 min
utes after hybridization is complete. Wash temperature and
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achieve a desired degree of stringency by applying the basic
principles that govern hybridization reactions and duplex sta
bility, as knoWn to those skilled in the art and described

further beloW (see, e.g., Sambrook et al., 1989). The hybrid
ization temperature for hybrid duplexes anticipated to be less
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than 50 base pairs in length optimally is 5 to 10° C. beloW the

melting temperature (Tm) of the duplex, Where Tm is deter
mined according to the folloWing equations. For hybrids less
than 18 base pairs in length, Tm (° C.):2(# ofA+T bases)+4(#
of #G+C bases). For hybrids above 18 base pairs in length,

expression control sequence having been introduced into the
host cell by transformation or transfection, for example, or by
any other suitable method.
As another embodiment of the disclosure, at least one

expression control sequence is integrated into the genome of
55

a recombinant host cell such that it is operably linked to a

polynucleotide sequence encoding a polypeptide of the dis

Tm (° C.):81.5+16.6(log10[Na+])+0.41(% G+C)—(600/N),

closure. In a further embodiment of the disclosure, at least one

expression control sequence is operably linked to a poly

Where N is the number of bases in the hybrid, and [Na+] is the
concentration of sodium ions in the hybridization buffer

([Na+] for 1><SSC:0.165M). Typically, each such hybridiz

the polynucleotide is expressed When appropriate molecules
(such as polymerases) are present. As one embodiment of the
disclosure, at least one expression control sequence is oper
ably linked to the polynucleotide of the disclosure in a recom
binant host cell or progeny thereof, the polynucleotide and/or

Wash salt concentration can be adjusted as necessary to
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nucleotide of the disclosure through the action of a trans
acting factor such as a transcription factor, either in vitro or in

ing polynucleotide has a length that is at least 15 nucleotides

a recombinant host cell.

(or more typically at least 18 nucleotides, or at least 20 nucle
otides, or at least 25 nucleotides, or at least 30 nucleotides, or
at least 40 nucleotides, or most commonly at least 50 nucle
otides), or at least 25% (at least 50%, or at least 60%, or at

In addition, a sequence encoding a signal peptide (native or
heterologous) that promotes secretion can be incorporated
into expression vectors. The choice of signal peptide or leader

least 70%, and most commonly at least 80%) of the length of
the polynucleotide of the disclosure to Which it hybridizes,

65

can depend on factors such as the type of host cells in Which

the recombinant polypeptide is to be produced. To illustrate,
examples of heterologous signal peptides that are functional
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in mammalian ho st cells include the signal sequence for inter
leukin-7 (IL-7) described in US. Pat. No. 4,965,195; the
signal sequence for interleukin-2 receptor described in Cos
man et al., Nature 312:768 (1984); the interleukin-4 receptor

of expressing heterologous polypeptides. Potentially suitable
bacterial strains include Escherichia coli, Bacillus sublilis,
Salmonella zyphimurium, or any bacterial strain capable of

expressing heterologous polypeptides. If the polypeptide is

signal peptide described in EP 367,566; the type I interleu
kin-1 receptor signal peptide described in US. Pat. No. 4,968,
607; and the type II interleukin-1 receptor signal peptide

made in yeast or bacteria, it may be necessary to modify the

polypeptide produced therein, for example by phosphoryla
tion or glycosylation of the appropriate sites, in order to
obtain a functional Kalirin polypeptide. Such covalent attach
ments may be accomplished using knoWn chemical or enZy

described in EP 460,846. A DNA sequence for a signal pep
tide (secretory leader) can be fused in frame to the polynucle
otide sequence of the disclosure so that the DNA is initially
transcribed, and the mRNA translated, into a fusion polypep

matic methods. The polypeptide may also be produced by
operably linking the isolated polynucleotide of the disclosure

tide comprising the signal peptide. A signal peptide that is

to suitable control sequences in one or more insect expression

functional in the intended host cells is one that promotes

vectors, and employing an insect expression system. Materi
als and methods for baculovirus/insect cell expression sys

extracellular secretion of the polypeptide in that host cell. The

signal peptide is cleaved from the polypeptide upon secretion

tems are commercially available in kit form from, e.g., lnvit

of polypeptide from the cell. The skilled artisan Will also

rogen, San Diego, Calif., USA. (the MaxBac® kit), and such

recogniZe that the position(s) at Which the signal peptide is

methods are Well knoWn in the art, as described in Summers

cleaved can differ from that predicted by computer program,

and Smith, Texas Agricultural Experiment Station Bulletin

and can vary according to such factors as the type of host cells

No. 1555 (1987), and LuckoW and Summers, Bio/Technol
ogy 6:47 (1 988). As used herein, an insect cell that is modi?ed

employed in expressing a recombinant polypeptide. A
polypeptide preparation can include a mixture of polypeptide

20

to express an exogenous polynucleotide of the disclosure is

molecules having different N-terminal amino acids, resulting

considered “transformed.” Cell-free translation systems may

from cleavage of the signal peptide at more than one site.
Established methods for introducing DNA into mamma

also be employed to produce polypeptides using RNAs

lian cells have been described (Kaufman, R. 1., Large Scale
Mammalian Cell Culture, 1990, pp. 15 69). Additional pro
tocols using commercially available reagents, such as Lipo
fectamine lipid reagent (Gibco/BRL) or Lipofectamine-Plus
lipid reagent, can be used to transfect cells (Felgner et al.,
Proc. Natl. Acad. Sci. USA 84:7413 7417, 1987). In addition,

25

derived from polynucleotide constructs disclosed herein. A
host cell that comprises an isolated polynucleotide of the
disclosure, preferably operably linked to at least one expres
sion control sequence, is a “recombinant host cell”.

The polypeptide of the disclosure may be prepared by
culturing transformed ho st cells under culture conditions suit
30

able to support expression of the recombinant polypeptide.

electroporation can be used to transfect mammalian cells

The resulting expressed polypeptide may then be puri?ed

using conventional procedures, such as those in Sambrook et

from such culture (i.e., from culture medium or cell extracts)
using knoWn puri?cation processes, such as selective precipi
tation With various salts, gel ?ltration and ion exchange chro
matography. The puri?cation of the polypeptide may also
include an a?inity column containing agents that Will bind to

al. (Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1 3,
Cold Spring Harbor Laboratory Press, 1989). Selection of
stable transformants can be performed using methods knoWn
in the art, such as, for example, resistance to cytotoxic drugs.
Kaufman et al., Meth. in EnZymology 185:487 511, 1990,
describes several selection schemes, such as dihydrofolate
reductase (DHFR) resistance. A suitable strain for DHFR
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selection is CHO strain DX-Bl 1, Which is de?cient in DHFR
(Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216

40

4220, 1980). A plasmid expressing the DHFR cDNA can be
introduced into strain DX-Bl 1, and only cells that contain the
plasmid can groW in the appropriate selective medium. Other
examples of selectable markers that can be incorporated into

the polypeptide; one or more column steps over such a?inity
resins as concanavalin A-agarose, heparin-toyopearl® or
Cibacrom blue 3GA Sepharose®; one or more steps involv

ing hydrophobic interaction chromatography using such res
ins as phenyl ether, butyl ether, or propyl ether; or immunoaf

?nity chromatography using an antibody that speci?cally
binds one or more Kalirin epitopes.

antibiotics, such as G418 and hygromycin B. Cells harboring

Alternatively, the polypeptide of the disclosure may also be
expressed in a form that Will facilitate puri?cation. For
example, it may be expressed as a fusion polypeptide, that is,
it may be fused With a maltose binding polypeptide (MBP),

the vector can be selected on the basis of resistance to these

glutathione-5-transferase (GST), thioredoxin (TRX) or poly

45

an expression vector include cDNAs conferring resistance to

compounds.
A number of types of cells may act as suitable host cells for

50

HlS. Kits for expression and puri?cation of such fusion
polypeptides are commercially available from NeW England

55

lnVitrogen, respectively. The polypeptide can also be tagged
With a non-Kalirin epitope and subsequently puri?ed by using
a speci?c antibody directed to such epitope. One such epitope
(FLAG®) is commercially available from Kodak (NeW

BioLab (Beverly, Mass.), Pharmacia (PiscataWay, N1.) and

expression of a kalirin polypeptide or active fragment thereof.
Mammalian ho st cells include, for example, the COS-7 line of

monkey kidney cells (ATCC CRL 1651) (GluZman et al., Cell
23:175, 1981), L cells, C127 cells, 3T3 cells (ATCC CCL
163), Chinese hamster ovary (CHO) cells, HeLa cells, BHK
(ATCC CRL 10) cell lines, the CVl/EBNA cell line derived
from the African green monkey kidney cell line CV1 (ATCC
CCL 70) as described by McMahan et al. (EMBO J. 10: 2821,

1991), human kidney 293 cells, human epidermal A431 cells,
human Colo205 cells, other transformed primate cell lines,
normal diploid cells, cell strains derived from in vitro culture
of primary tissue, primary explants, HL-60, U937, HaK or
Jurkat cells. Alternatively, the polypeptide may be produced
in loWer eukaryotes such as yeast or in prokaryotes such as
bacteria. Suitable yeast strains include Saccharamyces cer

evisiae,

Haven, Conn.). Finally, one or more reverse-phase high per

formance liquid chromatography (RP-HPLC) steps employ
ing hydrophobic RP-HPLC media, e.g., silica gel having
60

pendant methyl or other aliphatic groups, can be employed to
further purify the polypeptide. Some or all of the foregoing
puri?cation steps, in various combinations, can also be

employed to provide a substantially homogeneous isolated
recombinant polypeptide. The polypeptide thus puri?ed is
substantially free of other mammalian polypeptides and is
65

de?ned in accordance With the disclosure as an “isolated

Schizosaccharomyces pombe, Kluyveromyces

polypeptide.” The described puri?cation method may be used

strains, Candida spp., Pichia spp. or any yeast strain capable

to isolate Kalirin and Kalirin fragments as Well as antibodies
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that bind to Kalirin polypeptides, fragments, variants, binding

discovering other novel polynucleotides; for selecting and

partners etc. The polypeptide of the disclosure may also be

making oligomers for attachment to a “gene chip” or other

expressed as a product of transgenic animals, e.g., as a com

support, including for examination of expression patterns; to
raise anti-polypeptide antibodies using DNA immunization

ponent of the milk of transgenic coWs, goats, pigs, or sheep
Which are characterized by containing somatic or germ cells
into Which has been inserted a polynucleotide encoding a

techniques; as an antigen to raise anti-DNA antibodies or

elicit another immune response, and for use in gene therapy.

Uses of Kalirin polypeptides and fragmented polypeptides

human Kalirin polypeptide.
It is also possible to utilize an af?nity column comprising a

include, but are not limited to, the folloWing: purifying

polypeptide capable of binding to Kalirin polypeptides, such

polypeptides and measuring the activity thereof; delivery

as a monoclonal antibody generated against Kalirin or against

agents; therapeutic and research reagents; molecular Weight
and isoelectric focusing markers; controls for peptide frag
mentation; identi?cation of unknoWn polypeptides; and
preparation of Kalirin-speci?c antibodies. Any or all poly

an antigenic fragment thereof, to af?nity-purify expressed
Kalirin polypeptides. These Kalirin polypeptides can be
removed from an a?inity column using conventional tech
niques, e.g., in a high salt elution buffer and then dialyzed into

nucleotides suitable for these uses are capable of being devel
oped into reagent grade materials or kit format for commer
cialization as products. Methods for performing the uses
listed above are Well knoWn to those skilled in the art. Refer
ences disclosing such methods include Without limitation

a loWer salt buffer for use or by changing pH or other com

ponents depending on the a?inity matrix utilized, or be com

petitively removed using the naturally occurring substrate of
the a?inity moiety, such as a polypeptide derived from the

disclosure. In this aspect of the disclosure, Kalirin-binding
polypeptides, such as the anti-Kalirin antibodies of the dis
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closure or other polypeptides that can interact With Kalirin or

fragments thereof, can be bound to a solid phase support such
as a column chromatography matrix or a similar substrate

suitable for identifying, separating, or purifying cells that
express polypeptides of the disclosure on their surface.

25

Adherence of Kalirin-binding polypeptides of the disclosure
to a solid phase contacting surface can be accomplished by
any means, for example, magnetic microspheres can be
coated With these polypeptide-binding polypeptides and held
in the incubation vessel through a magnetic ?eld. Suspen

30

“Molecular Cloning: A Laboratory Manual”, 2d ed., Cold
Spring Harbor Laboratory Press, Sambrook, 1., E. F. Fritsch
and T. Maniatis eds., 1989, and “Methods in Enzymology:
Guide to Molecular Cloning Techniques”, Academic Press,
Berger, S. L. and A. R. Kimmel eds., 1987.
Among the uses of the disclosed Kalirin polynucleotides,
and combinations of fragments thereof, is the use of frag
ments as probes or primers. Such fragments generally com
prise at least about 17 contiguous nucleotides of a DNA
sequence. In other embodiments, a DNA fragment comprises
at least 30, or at least 60, contiguous nucleotides of a DNA

sequence. The basic parameters affecting the choice of

hybridization conditions and guidance for devising suitable

sions of cell mixtures are contacted With the solid phase that

has such polypeptide-binding polypeptides thereon. Cells

conditions are set forth by Sambrook et al., 1989 and are

having polypeptides of the disclosure on their surface bind to

described in detail above. Using knoWledge of the genetic

the ?xed Kalirin-binding polypeptide and unbound cells then
are Washed aWay. This af?nity-binding method is useful for

code in combination With the amino acid sequences set forth
35

purifying, screening, or separating such Kalirin-expressing

above, sets of degenerate oligonucleotides can be prepared.

cells from solution. Methods of releasing positively selected

Such oligonucleotides are useful as primers, e.g., in poly
merase chain reactions (PCR), Whereby DNA fragments are

cells from the solidphase are knoWn in the art and encompass,
for example, the use of enzymes. Such enzymes are prefer

primers can be used as probes for non-human genetic librar

ably non-toxic and non-injurious to the cells and are prefer

isolated and ampli?ed. In certain embodiments, degenerate
40

ably directed to cleaving the cell-surface binding partner.
Alternatively, mixtures of cells suspected of containing

sequence tag) or DNA libraries. Homologous sequences
identi?ed by this method Would then be used as probes to

polypeptide-expressing cells of the disclosure ?rst can be

incubated With a biotinylated Kalirin-binding polypeptide of
the disclosure. The resulting mixture then is passed through a
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column packed With avidin-coated beads, Whereby the high
a?inity of biotin for avidin provides the binding of the
polypeptide-binding cells to the beads. Use of avidin-coated
beads is knoWn in the art. See Berenson, et al. J. Cell. Bio
chem., 10Dz239 (1986). Wash of unbound material and the

identify non-human Kalirin homologues.
The polynucleotides encoding Kalirin polypeptides, and
the disclosed fragments and combinations of these polynucle
otides, can be used by those skilled in the art as a chromosome
marker. In addition, polynucleotides of the disclosure or a
fragment thereof can be used as a positional marker to map

50

release of the bound cells is performed using conventional
methods.

The polynucleotides encoding the Kalirin polypeptides
provided by the disclosure can be used for numerous diag
nostic or other useful purposes. The polynucleotides of the

ies. Such libraries Would include but are not limited to cDNA

libraries, genomic libraries, and even electronic EST (express
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other genes of unknoWn location. Useful techniques include,
but are not limited to, using the Kalirin polynucleotide
sequence or portions thereof, including oligonucleotides, as a
probe in various Well-knoWn techniques such as radiation

hybrid mapping (high resolution), in situ hybridization to
chromosome spreads (moderate resolution), and Southern

disclosure can be used to express recombinant Kalirin

blot hybridization to hybrid cell lines containing individual

polypeptide for analysis, characterization or therapeutic use;
as markers for tissues in Which the corresponding polypeptide
is preferentially expressed (either constitutively or at a par

human chromosomes (loW resolution).
The polynucleotides encoding Kalirin polypeptides, and

ticular stage of tissue differentiation or development or in
disease states); as molecular Weight markers on Southern
gels; as chromosome markers or tags (When labeled); to com

the disclosed fragments and combinations of these polynucle
60

rin gene or variants thereof. By this means, one can distin

pare With endogenous DNA sequences in patients to identify
potential genetic disorders; as probes to hybridize and thus
discover novel, related DNA sequences; as a source of infor

mation to derive PCR primers for genetic ?ngerprinting; as a
probe to “subtract-out” knoWn sequences in the process of

otides can be used by one skilled in the art using Well-knoWn

techniques to analyze abnormalities associated With the Kali
gui sh conditions in Which this marker is rearranged or deleted
65

and can use this information for diagnosing certain medical
disorders. Kalirin DNA furthermore can be used in develop
ing treatments for any disorder mediated (directly or indi

rectly) by defective, or insuf?cient amounts of, the genes
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corresponding to the polynucleotides of the disclosure. Dis
closure herein of native nucleotide sequences permits the
detection of defective genes, and the replacement thereof
With a normal Kalirin gene using gene therapy techniques

tion and by liposome injections may be achieved using meth
ods that are Well knoWn in the art.

diagnostic assays, and by comparison of a native nucleotide

The disclosure also provide methods and compositions for
determining diagnosing or determining the risk of a subject
for developing senile dementia (e. g., AD). The method com
prises monitoring levels of kalirin polypeptides or activity

sequence disclosed herein With that of a gene derived from a

and/or detecting gene expression (mRNA levels) in a subject.

person suspected of harboring a defect in a Kalirin gene.
In one aspect the disclosure relates to a method to identify
modulators useful to treat, prevent or ameliorate pathological
conditions associated With excess iNOS activity or NO,

described herein may be obtained from a commercial source

knoWn in the art. Defective genes can be detected in in vitro

Suitable antibodies for use in diagnostic methods and kits

or produced according to conventional methods based upon

the polypeptide sequence provided herein. Such antibodies

including, but not limited to AlZheimer’s Disease comprising:
a) assaying for the ability of a candidate agent to modulate
kalirin activity or production and Which can further include b)

may include, but are not limited to polyclonal antibodies,
monoclonal antibodies (mAbs), humaniZed or chimeric anti

assaying for the ability of an identi?ed agent to reverse the
pathological effects observed in animal models of said con
ditions and/or in clinical studies With subjects With any one or

ments, fragments produced by a Fab expression library, anti

more of said conditions.

For the production of antibodies to the polypeptides dis
cussed herein, various host animals may be immuniZed by
injection With the polypeptides, or a portion thereof. Such
host animals may include, but are not limited to, rabbits, mice,
goats, chicken, and rats. Various adjuvants may be used to
increase the immunological response, depending on the host
species, including, but not limited to, Freund’s (complete and
incomplete), mineral gels such as aluminum hydroxide, sur
face active substances such as lysolecithin, pluronic polyols,

Conventional screening assays (both in vitro and in vivo)
may be used to identify agents the modulate kalirin protein
activity and/or gene expression. Protein activity levels, e.g.,
enZymatic activity levels, can be assayed in a subject using a

bodies, single chain antibodies, Fab fragments, F(ab')2 frag

idiotypic (anti-Id) antibodies, and epitope-binding fragments
of any of the above.
20

biological sample from the subject using conventional
enZyme activity assays (e.g., to determine iNOS activity of
NO in a sample). Gene expression (e.g., mRNA levels) may
also be determined using methods familiar to one of skill in

the art, including, for example, conventional Northern analy
sis or commercially available microarrays. Additionally, the

polyanions, peptides, oil emulsions, keyhole limpet
hemocyanin, dinitrophenol, and potentially useful human

effect of test agent on protein levels can be detected With an

ELISA antibody-based assay or ?uorescent labelling reaction
assay. These techniques are readily available for high
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Detection method for use With antibodies are knoWn in the

throughput screening and are familiar to one skilled in the art.

Data gathered from these studies Would be used to identify
kalirin agonists With therapeutic usefulness for the treatment
of pathological conditions discussed herein. Such agonists
could be further assayed in conventional live animal models

art. For example, antibody detection may be achieved using
standard ELISA, FACS analysis, and standard imaging tech
35

familiar to one of skill in the art and/ or in clinical trials With
humans according to conventional methods to assess the abil

ity of said agent/agonist to treat, prevent or ameliorate any
one or more of said conditions in vivo.
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In another aspect, the disclosure relates to a method to treat,

prevent or ameliorate pathological conditions associated With
iNOS activity and NO including, but not limited to, AlZhe

imer’s Disease, comprising administering to a subject in need
thereof a pharmaceutical composition comprising an effec

coupling (i.e., physically linking) the antibody to a detectable
substance. Examples of detectable substances include vari
ous enZymes, prosthetic groups, ?uorescent materials, lumi
nescent materials, bioluminescent materials, and radioactive
materials.
In another aspect, the disclosure provides methods of treat
ing neurodegenerative disorder and/or senile dementia com

gene therapy techniques. Kalirin gene products or therapeutic
45

treatments can be obtained via homologous recombination,

or “gene targeting,” techniques. Such techniques employ the
introduction of exogenous transcription control elements
(such as the CMV promoter or the like) in a particular prede

The pharmaceutical compositions can comprise sub

termined site on the genome, to induce expression of the
50

endogenous polynucleotide sequence of interest (see, for
example, US. Pat. No. 5,272,071). The location of integra
tion into a host chromosome or genome can be easily deter

mined by one of skill in the art, given the knoWn location and

double or single stranded RNA directed to an appropriate

nucleotide sequence of nucleic acid encoding, for example,
iNOS. These inhibitory molecules may be created using con

niques used in vitro or in vivo. Detection can be facilitated by

prising (i) stimulating production of kalirin in vivo and (ii) by

tive amount of a kalirin agonist.

stances that inhibit the expression of other agents associated
With the modulation of NO including, iNOS and homologs
thereof. Such molecules include riboZymes, antisense oligo
nucleotides, triple helix DNA, RNA aptamers, siRNA and/or

adjuvants such as BCG (bacille Calmette-Guerin) and
Corynebaczerium parvum.

sequence of the gene. In one embodiment, the disclosure
55

contemplates the introduction of exogenous transcriptional

ventional techniques by one of skill in the art Without undue

control elements in conjunction With an ampli?able gene, to

burden or experimentation. For example, changes in poly

produce increased amounts of the gene product, again, With

nucleotide expression in a cell can be obtained by designing
vectors capable of expression of a desired molecule (e.g., a

out the need for isolation of the gene sequence itself from the
host cell.
Because mutant or reduced kalirin polypeptide correlates

kalirin 7 polynucleotide, antisense iNOS and the like) by
operably liking the desired molecule to control regions, ie to
promoters, enhancers, and introns.
Vectors may be introduced into cells or tissues by many
available means, and may be used in vivo, in vitro or ex vivo.
For ex vivo therapy, vectors may be introduced into stem cells

taken from the patient and clonally propagated for autologous
transplant back into that same patient. Delivery by transfec

60

With the excessive accumulation nitric oxide, the regulation

65

of kalirin expression ?nds use in gene therapy to treat neuro
degeneratie diseases associated With excess iNOS activity or
NO production. In particular, to reduce the activity of iNOS or
nitric oxide production, a functional kalirin gene or a poly
nucleotide encoding an active fragment of kalirin may be
introduced into cells at the sites of excess iNOS activity or NO
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production such that the cell expresses a therapeutically
effective amount of kalirin polypeptide or active fragment
thereof.

micelles, and liposomes. Liposomes are arti?cial membrane
vesicles Which are useful as delivery vehicles in vitro and in

vivo. It has been shoWn that large unilamellar vesicles (LUV),

Adenoviral, adeno-associated, herpes virus, vaccinia, ret

Which range in siZe from 0.2-4.0 um can encapsulate a sub

stantial percentage of an aqueous buffer containing large

roviral, or other viral vectors With the appropriate tropism for
cells likely to be involved in neurodegenerative diseases such

macro molecules. RNA, DNA and intact virions can be

encapsulated Within the aqueous interior and be delivered to
cells in a biologically active form (Fraley, et al., Trends Bio

as AD may be used as a gene transfer delivery system for a

therapeutic kalirin genetic construct. Viral vectors Which do
not require that the target cell be actively dividing, such as

chem. Sci., 6177, 1981). In addition to mammalian cells,
liposomes have been used for delivery of polynucleotides in

adenoviral and adeno-as sociated vectors, are particularly use
ful When the cells are accumulating but not particularly pro
liferative. Numerous vectors useful for this purpose are gen

plant, yeast andbacterial cells. In order for a liposome to be an

e?icient gene transfer vehicle, the folloWing characteristics
should be present: (1) encapsulation of the genes of interest at

erally knoWn (Miller, Human Gene Therapy 15-14, 1990;
Friedman, Science 24411275-1281, 1989; Eglitis and Ander

high e?iciency While not compromising their biological
activity; (2) preferential and substantial binding to a target
cell in comparison to non-target cells; (3) delivery of the

son, BioTechniques 61608-614, 1988; Tolstoshev and Ander

son, Current Opinion in Biotechnology 1155-61, 1990; Sharp,

aqueous contents of the vesicle to the target cell cytoplasm at

The Lancet 33711277-1278, 1991; Cornetta et al., Nucleic
Acid Research and Molecular Biology 361311-322, 1987;

Anderson, Science 2261401-409, 1984; Moen, Blood Cells
171407-416, 1991; and Miller and Rosman, Biotechniques
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71980-990, 1989; Le Gal La Salle et al., Science 2591988-990,

high e?iciency; and (4) accurate and effective expression of
genetic information (Mannino, et al., Biotechniques, 61682,
1 988).
The composition of the liposome is usually a combination

1993; and Johnson, Chest 107177S-83S, 1995). Retroviral

of phospholipid, particularly high-phase-transition-tempera

vectors are particularly Well developed and have been used in

ture phospholipids, usually in combination With steroids,
especially cholesterol. Other phospholipids or other lipids
may also be used. The physical characteristics of liposomes
depend on pH, ionic strength, and the presence of divalent

clinical settings (Rosenberg et al., N. Engl. J. Med 3231370,
1990; Anderson et al., US. Pat. No. 5,399,346).
By inserting a kalirin polynucleotide or oligonucleotide of
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cations.
The targeting of liposomes can be classi?ed based on ana
tomical and mechanistic factors. Anatomical classi?cation is

interest into the viral vector, along With another gene Which
encodes the ligand for a receptor on a speci?c target cell, for
example, the vector is noW target speci?c. Viral vectors can be

made target speci?c by attaching, for example, a sugar, a
glycolipid, or a protein. Preferred targeting is accomplished
by using an antibody to target the viral vector. Those of skill
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based on the level of selectivity, for example, organ-speci?c,

cell-speci?c, and organelle-speci?c. Mechanistic targeting
can be distinguished based upon Whether it is passive or

in the art Will knoW of, or can readily ascertain Without undue

active. Passive targeting utiliZes the natural tendency of lipo

experimentation, speci?c polynucleotide sequences Which

somes to distribute to cells of the reticulo-endothelial system

can be inserted into the viral genome or attached to a viral 35 (RES) in organs Which contain sinusoidal capillaries. Active

envelope to alloW target speci?c delivery of the viral vector
containing a kalirin polynucleotide or oligonucleotide, e.g.,

the human Wild-type kalirin polynucleotide.
Since recombinant viruses are defective, they require assis
tance in order to produce infectious vector particles. This
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naturally occurring sites of localiZation.

assistance can be provided, for example, by using helper cell
lines that contain plasmids encoding all of the structural
genes of the virus under the control of regulatory sequences
Within the viral genome. These plasmids are missing a nucle
otide sequence Which enables the packaging mechanism to

For any of the above approaches, the therapeutic kalirin
polynucleotide or oligonucleotide construct is applied to the
site Where iNOS activity is to be controlled or NO production
45

recogniZe a polynucleotide transcript for encapsidation.
Which the packaging signal is intact, but the structural genes
50

packaged and vector virion produced.
Non-viral approaches may also be employed for the intro
duction of therapeutic kalirin polynucleotide or oligonucle
55

fragment thereof may be introduced by the techniques of
colloidal dispersion (Felgner et al., Proc. Natl. Acad. Sci.
USA 8417413, 1987; Ono et al., Neuroscience Lett 1171259,
1990; Brigham et al., Am. J. Med. Sci. 2981278, 1989; Staub

inger and Papahadjopoulos, Meth. EnZ. 1011512, 1983); asia
lorosonucoid-polylysine conjugation (Wu and Wu, J. Biol.

ci?c expression). Furthermore, kalirin production may be
regulated by any desired mammalian regulatory element. For
example, if desired, enhancers knoWn to direct preferential
gene expression can be used to direct kalirin expression. Such

enhancers include, Without limitation, those enhancers Which
60

are characteriZed as tissue or cell speci?c in their expression.
Alternatively, if a kalirin genomic clone is utiliZed as a

therapeutic construct, kalirin expression is regulated by its
cognate regulatory sequences or, if desired, by regulatory

Chem. 263114621, 1988; Wu et al., J. Biol. Chem. 264116985,
1989); or, less preferably, microinjection under surgical con

sequences derived from a heterologous source, e. g., any of the

promoters or regulatory elements described above.

ditions (Wolff et al., Science 24711465, 1990).
Colloidal dispersion systems include macromolecule com

activity or NO production is desired.
In the gene therapy constructs, kalirin polynucleotide or
oligonucleotide expression is directed from any suitable pro
moter (e.g., the human cytomegalovirus, simian virus 40,
actin or adenovirus constituative promoters; or the cytokine
or metallothionein promoters for activated synoviocyte spe

otide into cells otherWise predicted to have excessive iNOS
activity or NO accumulation. For example, kalirin or an active

reduced (for example, by injection), but may also be applied
to tissue in the vicinity of the iNOS or NO production or even
to a blood vessel supplying the cells Where control of iNOS

These cell lines produce empty virions, since no genome is
packaged. If a viral vector is introduced into such cells in
are replaced by other genes of interest, the vector can be

targeting, on the other hand, involves alteration of the lipo
some by coupling the liposome to a speci?c ligand such as a
monoclonal antibody, sugar, glycolipid, or protein, or by
changing the composition or siZe of the liposome in order to
achieve targeting to organs and cell types other than the
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Less preferably, kalirin gene therapy is accomplished by

plexes, nanocapsules, microspheres, beads, and lipid-based

direct administration of a kalirin mRNA to a cell predicted to

systems including oil-in-Water emulsions, micelles, mixed

require iNOS or NO control. This mRNA may be produced

